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| INTRODUC TI ON
Esophageal cancer is the eighth most common cancer and the sixth most common cause of cancer mortality worldwide, resulting in approximately 400 000 deaths per year.
1 Despite recent remarkable advances in multidisciplinary therapies including surgery, chemotherapy, radiotherapy, and chemoradiotherapy, the prognosis of esophageal cancer patients remains poor.
2
Immunotherapy has important clinical applications with potential favorable outcomes. Specifically, immunotherapy targeting the programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoints has already been approved for many types of cancer. 3, 4 In fact, several innovative clinical trials evaluating PD-1/PD-L1 signal blocking agents have reported efficacy in patients with numerous types of malignancies, including gastrointestinal cancer, in recent years. [5] [6] [7] [8] However, the majority of patients with certain types of cancer do not respond, strongly suggesting that additional immunoregulatory pathways control the effectiveness of immunosurveillance in human cancers. has recently been the focus of drug discovery efforts as a potential therapeutic target.
In a previous study, we reported that IDO1 expression was associated with an unfavorable clinical outcome in esophageal cancer.
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Other studies have also reported on the relationship between IDO1 expression and clinical outcomes in several types of cancer [11] [12] [13] [14] [15] [16] ( 
| MATERIAL S AND ME THODS

| Specimens
We analyzed 242 formalin-fixed, paraffin-embedded (FFPE) esopha- 
| Measurement of IDO1 promoter methylation and long interspersed nucleotide element-1 using pyrosequencing
Genomic DNA was collected from frozen esophageal cancer specimens using a QIAamp DNA Mini Kit (Qiagen). Genomic DNA unmethylated cytosines were converted to uracil with sodium bisulfite using an EpiTect Bisulfite kit (Qiagen). To measure IDO1 promoter methylation, we undertook PCR and pyrosequencing using a PyroMark Q24 System (Qiagen). Pyrosequencing reactions were carried out with the reverse primer biotinylated at the 5′-end (forward primer 5′-
GTAAGTTTGTGGTTTATTTTAGAGGTATTG-3′, reverse primer [bio-
tin] 5′-ACTATTTCTCTTTTCTCCTTTTAATCA-3′, sequencing primer 5′-GGAAGTTAAAGAAGAAATTAAG-3′). Polymerase chain reaction was carried out using the PyroMark PCR Kit (Qiagen), following the manufacturer's recommendations with an annealing temperature of 50°C ( Figure 1 ). We also performed PCR and pyrosequencing of long interspersed nucleotide element-1 (LINE-1) as previously described.
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F I G U R E 1 Pyrosequencing assay used to measure the indoleamine 2, 3-dioxygenase 1 (IDO1) promoter methylation level. A, IDO1 promoter hypomethylated tumor (methylation level, 9%). B, IDO1 promoter hypermethylated tumor (methylation level, 56%). The percentages (in blue) are the proportion of C at the CpG site after bisulfite conversion, and the methylation level of the CpG site was estimated by the proportion of C (%) 
| Cell lines
| Treatment with 5-azacytidine
Cells were seeded in a 100-mm dish and cultured for 24 hours. To demethylate methylated CpG sites, cells were continuously treated with 5-azacytidine (5-AZA; 100 nmol/L-concentration) (Wako, Osaka, Japan)
for an additional 72 hours. The medium was replaced every 24 hours.
| Statistical methods
All statistical calculations were carried out using JMP version 10 (SAS DNA methylation. 23 The IDO1 promoter methylation levels were also decreased by 5-AZA treatment. In addition, we determined whether IFNγ influences the IDO1 promoter methylation levels and IDO1 expression levels ( Figure S1 ). From those experiments, we found that IFNγ did not influence IDO1 promoter methylation levels, but did influence IDO1 expression levels. These findings suggested that the changes in DNA methylation levels influenced IDO1 expression levels apart from the influence of IFNγ.
| Correlation between IDO1 expression and IDO1 promoter methylation levels
To confirm the association between IDO1 expression and IDO1 methylation levels, we measured methylation levels of the CpG site in the IDO1 promoter in 40 frozen samples from esophageal cancer patients. We found that the methylation level of the CpG site in the IDO1 promoter inversely correlated with the IDO1 mRNA expression level (correlation rate: −0.47, P = .0019) (Figure 3 ). These data suggest that DNA hypermethylation in the IDO1 promoter might indeed be involved in the reduction of IDO1 transcription observed in esophageal cancer.
| Evaluation of the association of IDO1 methylation levels and clinicopathological variables
Next, we quantified IDO1 methylation in 242 FFPE cancer speci- we found that the IDO1 methylation level was associated with the F I G U R E 2 Indoleamine 2, 3-dioxygenase 1 (IDO1) mRNA expression levels and IDO1 promoter methylation levels in 5 esophageal cell lines were measured before and after 5-azacytidine (5-AZA) treatment. Global DNA methylation levels were evaluated by measuring long interspersed nucleotide element-1 (LINE-1) methylation levels presence of preoperative treatment (chemotherapy, n = 53; chemoradiotherapy, n = 30) ( Table 2 ).
| Hypomethylation of IDO1 promoter and patient survival
During follow-up of the 242 patients, there were a total of 116 esophageal cancer recurrences and 91 deaths that were confirmed to be attributable to esophageal cancer. The median follow-up time for censored patients was 3.9 years. In the Kaplan-Meier analysis, the IDO1 hypomethylation group showed a significantly shorter overall survival (OS) (log-rank P = .011) (Figure 4 ). In univariate Cox regression analysis, patients with IDO1 promoter hypomethylation showed significantly higher overall mortality than those with IDO1-negative tumors (HR 1.75; 95% confidence interval, 1.120-2.677; P = .015].
| Survival analysis of interaction between IDO1 and other variables
We next determined whether the influence of IDO1 promoter meth- 
| D ISCUSS I ON
We undertook this study to examine the mechanism involved in regulating IDO1 expression in curatively resected esophageal cancer patients. Indoleamine 2, 3-dioxygenase 1 is one of the most important immunological metabolic enzymes that induce immune tolerance. 24 Therefore, many clinical trials have been carried out to investigate the effects of the IDO1 inhibitors epacadostat and indoximod in several cancer types, including gastrointestinal cancer. [25] [26] [27] Although these studies are ongoing with some encouraging results, expectations are high that IDO1 will be an important therapeutic target. Indoleamine 2, 3-dioxygenase 1 is also recognized as a resistance mechanism to immune checkpoint blockade in cancer 28 ;
therefore, elucidation of the mechanism of regulation of IDO1 expression in esophageal cancer could help improve immunotherapeutic strategies for this disease.
Some previous studies have reported on the mechanism of IDO1 expression. In dendritic cells, IFNβ, IFNγ, and tumor necrosis factor-α activate the JAK/STAT pathway that results in the activation of IDO1.
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These inflammatory cytokines have also been shown to stimulate the activity of IDO1 in cancer cells. Furthermore, in breast cancer, it has been reported that IDO1 expression was regulated by IDO1 promoter methylation in estrogen receptor-positive cases. Specifically, hypomethylation of CpGs in the IDO1 promoter was associated with JAK/STAT pathway signaling and increased IDO1 activity. 17 In lung cancer, sustained IDO1 activity was reported to occur, resulting from sustained activity of the aryl hydrocarbon receptor, interleukin-6, and STAT3 signaling loop. 30 In cervical cancer, it has been suggested that the expression of IDO1 was induced by inflammatory cytokines that were produced in the tumor stroma; however, this has not yet been proved.
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To our knowledge, there has been no report of a particular mechanism involved in regulating IDO1 activity in esophageal cancer. Based on past studies in other types of cancer, we considered that the most important mechanism might involve methylation of CpGs in the IDO1 promoter and therefore investigated the relationship between methylation level and IDO1 expression level. We found that demethylation significantly induced higher expression of IDO1 in all esophageal cancer cell lines. In addition, we discoveres IDO1 mRNA expression levels and IDO1 promoter mthylation level have inverse correretion in frozen samples. Furthermore, experiments using 242 FFPE samples showed that there was a strong association between methylation level and poor prognosis in patients with esophageal cancer. Therefore, our results are evidence that epigenetic hypomethylation induces high expression of IDO1 and contributes to malignant behavior in esophageal cancer. As we summarized in Table 1 , the relationship between IDO1 expression and prognosis has been examined by various methods, including PCR and immunohistochemistry. Most reports have concluded that mRNA, protein, and hypomethylation were associated with poor prognosis, regardless of the type of cancer. However, even in the same cancer, the reported significance of IDO1 expression differs, depending on tissue type or gene type. 32, 33 Conversely, it has been reported that IDO1 expression prolongs OS in renal cancer. 34 Thus, it would be necessary to validate the significance if IDO1 expression using the same samples with multiple measurement methods.
In the clinicopathological analysis, only preoperative treatment was associated with IDO1 promoter methylation levels. Figure S3 ), IDO1 promoter methylation, and OS ( Figure 5 ). Therefore, it is suggested that there are complex mechanisms that determine the influence of methylation on IDO1 protein expression, malignant behavior from IDO1, and absence of CD8 + TIL.
Our analysis has revealed that age and the absence of comorbidity influenced the relationship between IDO1 promoter methylation and OS rates. Interestingly, a past report has suggested that IDO1 expression was higher in young, compared to old, prostate cancer patients. 38 Furthermore, IDO1 depletion has been reported to be associated with development of pulmonary hypertension 39 or diabetes. 40 From these results, IDO1 was identified as an oncogene in esophageal cancer, but it could involve very complicated mechanisms in relation to various diseases. In addition, in the multivariate analysis, IDO1 promoter hypomethylation was not a statistically independent prognostic factor (Table S1 ). In our previous study, we showed that IDO1 protein expression was an independent prognostic factor. 10 Therefore, further studies are necessary to examine whether histological type, type of preoperative treatment, or other factors influence the characterization of IDO1 promoter methylation. is necessary to analyze factors that change with IDO1 expression, including kynurenine or tryptophan, to confirm the mechanism in more detail.
In summary, this study suggests that methylation of CpG sites in the IDO1 promoter regulated IDO1 expression levels and was associated with poor prognosis in esophageal cancer patients. Thus, additional studies are needed to test this mechanism as a potentially new therapeutic target or prognostic biomarker for esophageal cancer. In future, development of a multidisciplinary treatment strategy, including immunotherapy, is expected to contribute to developing individualized therapeutic regimens in esophageal cancer.
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F I G U R E 4 A, Distribution of indoleamine 2, 3-dioxygenase 1 (IDO1) promoter methylation levels in 242 esophageal cancers. B, Kaplan-Meier curves for overall survival among patients with esophageal cancer according to IDO1 promoter methylation levels F I G U R E 5 Relationship between indoleamine 2, 3-dioxygenase 1 (IDO1) promoter methylation in esophageal cancer and overall survival. Shown are the log e (hazard ratio [HR]) plots of the overall survival rates in the IDO1 promoter hypomethylation and IDO1 promoter hypermethylation groups. PS, performance status; TIL, tumor infiltrating lymphocyte
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